Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations (readOnlyHint=true, idempotentHint=true, destructiveHint=false) are consistent. The description adds valuable behavioral details: it pulls latest 10-K revenue/net income/cash/debt for companies (with proper fiscal year handling), and FAERS counts/FDA approvals/trial counts for drugs. Also states results are sorted by primary metric and returns paired data with citation URIs.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is somewhat long but front-loaded with common trigger phrases. Every sentence adds value, explaining triggers, entity types, data sources, and output features. Could be slightly shortened but is well-structured.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given no output schema, the description explains return value (paired data + citation URIs) and mentions sorting. It covers both entity types with specific metrics. Missing explicit output format but acceptable for a comparison tool with only 2 parameters.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% with descriptions for both parameters. The description adds practical usage details: 'values' expects tickers/CIKs for companies and drug names, with min 2, max 5 items. It also clarifies what metrics are pulled per type, which goes beyond the schema's type enum.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool performs side-by-side comparison of 2-5 companies or drugs. It lists specific trigger phrases ('Compare X and Y', 'X vs Y', etc.) and distinguishes between entity types with distinct data sources (SEC EDGAR for companies, FAERS/FDA for drugs). This differentiates it from sibling tools like entity_profile.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'ALWAYS PREFER over sequential single-pack lookups when comparing entities,' giving clear context for when to use. It does not list explicit exclusions or alternatives beyond sequential lookups, but the guidance is strong and sufficient.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation2/5

Several tools occupy the same "answer a factual question" niche: ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, validate_claim, and bet_research all route to the same underlying catalog, so an agent must parse subtle differences to pick correctly. scan_competitor_ai_presence also wraps ai_visibility_check, adding another near-duplicate. The detailed descriptions help, but the boundaries are genuinely fuzzy.

Naming Consistency3/5

The set mixes several conventions: fac_*, polymarket_*, and pipeworx_* prefixes coexist with bare verbs (remember, recall, forget, subscribe, unsubscribe) and noun phrases (entity_profile, recent_changes, bet_research). ask_pipeworx_beta/grounded use a suffix pattern while pipeworx_feedback/trending use a prefix, so there is no single predictable scheme. Still, most names are readable and describe what they do.

Tool Count2/5

36 tools is well above the 25+ threshold and creates a heavy surface for any client to load and reason about. The broad data-platform scope explains some of the count, but many tools are meta-variants of the same query/research capability rather than genuinely distinct operations.

Completeness4/5

For the server's apparent purpose—authoritative data lookup, research, prediction-market analysis, and account/feed management—the surface covers the core lifecycle: query, entity resolution, profiles, comparisons, recent changes, claim verification, subscriptions, alerts, and memory. Minor gaps exist (no direct tool to fetch a pipeworx:// citation URI; no raw per-pack access), but most workflows are supported.